# US 2003/0216423 A1 · Stable liquid and solid formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216423 A1
- Document ID: US20030216423A1
- Status: Published application
- Kind: A1
- Application number: 10/276,637
- Filed: 2002-11-18
- Published: 2003-11-20
- Earliest claimed: 2000-05-24
- Inventors: Sergio Ulloa; Ramos Villacampa
- Web page: https://patentgrep.com/patent/US20030216423A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Stable pharmaceutical compositions containing non-sedating antihistamines such as loratadine and a nasal decongestant such as pseudoephedrine sulfate and at least one pharmaceutically acceptable carrier, and stable pharmaceutical compositions containing non-sedating antihistamines such as loratadine, nasal decongestants such as pseudoephedrine, and an expectorant such as Ambroxol and at least one pharmaceutically acceptable carrier which are stable to chemical and physical degradation and microbial contamination are disclosed.

## Claims

### Claim 1

A stable pharmaceutical composition comprising an effective amount of loratadine or a pharmaceutically acceptable salt thereof and an effective amount of nasal decongestant or a pharmaceutically acceptable salt thereof and optionally an effective amount of an expectorant or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

### Claim 2

A stable liquid pharmaceutical composition comprising an effective amount of loratadine or a pharmaceutically acceptable salt thereof and an effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable liquid carrier.

### Claim 3

A stable pharmaceutical composition comprising an effective amount of loratadine or a pharmaceutically acceptable salt thereof and an effective amount of nasal decongestant or a pharmaceutically acceptable salt thereof and an effective amount of an expectorant or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

### Claim 4

The pharmaceutical composition of any preceding claim wherein the nasal decongestant is pseudoephedrine or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1, 3)

The pharmaceutical composition of claim 1 or 3 wherein the stable pharmaceutical composition is a liquid dosage form and contains at least one pharmaceutically acceptable liquid carrier.

### Claim 6 (depends on 1, 3)

The pharmaceutical composition of claim 1 or 3 wherein the stable pharmaceutical composition is a solid dosage form.

### Claim 7 (depends on 2, 5)

The pharmaceutical composition of claim 2 or 5 which contains an antimicrobial effective amount of a sweetener, propylene glycol and glycerin.

### Claim 8 (depends on 1, 2, 3)

The pharmaceutical composition of claims 1,2 or 3 which contains about 0.4 to about 0.7 mg/ml of loratadine.

### Claim 9

A liquid pharmaceutical composition stable to microbial contamination comprising an effective amount of loratadine or a pharmaceutically acceptable salt thereof an effective amount of pseudoephedrine or phenylpropanolamine or a pharmaceutically acceptable salt thereof, and a combination of (1) a sweetener, (2) at least one pharmaceutically acceptable liquid carrier, and (3) an amount of a buffer system to sufficient maintain the pH in the range of about 3.0 to about 5.0.

### Claim 10

A stable pharmaceutical composition stable to microbial contamination comprising an effective amount of loratadine or a pharmaceutically acceptable salt thereof an effective amount of pseudoephedrine or phenylpropanolamine or a pharmaceutically acceptable salt thereof, and an effective amount of an expectorant or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 wherein the stable pharmaceutical composition is a liquid dosage form and contains a combination of (1) a sweetener, (2) at least one pharmaceutically acceptable liquid carrier, and (3) an amount of a buffer system to sufficient maintain the pH in the range of about 2.5 to about 5.0.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10 wherein the stable pharmaceutical composition is a solid dosage form.

### Claim 13 (depends on 9, 10)

The pharmaceutical composition of claim 9 or 10 wherein the sweetener is a combination of sodium saccharide and sorbitol.

### Claim 14

A stable liquid pharmaceutical composition comprising:
15 Ingredient mg/ml Loratadine 0.50 Pseudoephedrine Sulfate 6.00 Glycerin 200.00 Propylene Glycol 350.00 Sorbitol 70% Solution 225.00 Sodium Saccharin 0.40 Peach Flavor No. 609 2.50 Citric Acid, Anhydrous 0.64 Sodium Citrate 0.02 Purified Water q.s. To make 1.00 ml

### Claim 15

A stable liquid pharmaceutical composition comprising:
16 Ingredient mg/ml Loratadine 1.0 Pseudoephedrine Sulfate 6.00 Glycerin 200.00 Propylene Glycol 350.00 Sorbitol 70% Solution 225.00 Sodium Saccharin 0.40 Peach Flavor No. 609 2.50 Citric Acid, Anhydrous 0.64 Sodium Citrate 0.02 Purified Water q.s. To make 1.00 ml

### Claim 16

The liquid pharmaceutical composition of any preceding claim that is stable to microbial contamination for periods of at least 4 months, preferably up to 36 months storage at room temperature.

### Claim 17

The liquid pharmaceutical composition of any preceding claim that is stable to physical and chemical degradation of the active ingredients for periods of at least 4 months, preferably up to 36 months storage at room temperature.

### Claim 18

The liquid pharmaceutical composition of any preceding claim that is stable to microbial contamination and to physical and chemical degradation of the active ingredients for periods of at least 4 months, preferably up to 36 months storage at room temperature.

### Claim 19

The liquid pharmaceutical composition of any preceding claim that is substantially free of sugar such as glucose or sucrose and of ethanol and suitable for pediatric use.

### Claim 20

The use of loratadine and a nasal decongestant for the preparation of a liquid pharmaceutical composition for treatment of the symptoms associated with allergic reactions which comprises effective amount of a non-sedating antihistamine in combination with an effective amount of an nasal decongestant.

### Claim 21

The use of loratadine and a nasal decongestant for the preparation of a liquid pharmaceutical composition for treatment of the symptoms associated with allergic rhinitis and the common cold which comprises effective amount of a non-sedating antihistamine in combination with an effective amount of an nasal decongestant.

### Claim 22

The use of loratadine and a nasal decongestant for the preparation of a liquid pharmaceutical composition for treatment of the symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation which comprises effective amount of a non-sedating antihistamine in combination with an effective amount of an nasal decongestant.

### Claim 23

The use of a non-sedating antihistamine in combination with an expectorant and a nasal decongestant for the preparation of a medicament for the treatment of allergic and inflammatory respiratory conditions with cough, nasal congestion and the presence of mucus in the respiratory tract which comprises an effective amount of a non-sedating antihistamine in combination with an effective amount of an expectorant, and an effective amount of an nasal decongestant.

### Claim 24 (depends on 20, 21, 22, 23, 24)

The use of claim 20-24 wherein the decongestant is pseudoephedrine or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The use of any of the claims 20-24 wherein the liquid pharmaceutical composition is stable to microbial contamination for periods of at least 4 months, preferably up to 36 months storage at room temperature.

### Claim 26 (depends on 20, 21, 22, 23, 24)

The use of any of the claims 20-24 wherein the liquid pharmaceutical composition is stable to physical and chemical degradation of the active ingredients for periods of at least 4 months, preferably up to 36 months storage at room temperature.

### Claim 27 (depends on 20, 21, 22, 23, 24)

The use of any of the claims 20-24 wherein the liquid pharmaceutical composition is stable to microbial contamination and to physical and chemical degradation of the active ingredients for periods of at least 4 months, preferably up to 36 months storage at room temperature.
